| Literature DB >> 35983107 |
Prashant Kumar Sharma1, Sridhar Panaiyadiyan1, Santosh Kurra2, Raman Kumar2, Brusabhanu Nayak1, Seema Kaushal3, Alpana Sharma2, Rajeev Kumar1, Amlesh Seth1, Prabhjot Singh1.
Abstract
Introduction: Human papillomavirus (HPV) is a known risk factor of penile cancer (PeCa). However, studies evaluating its true association are limited. In this study, we aimed to estimate HPV prevalence and its true association with PeCa in terms of molecular biological activities. Materials andEntities:
Year: 2022 PMID: 35983107 PMCID: PMC9380453 DOI: 10.4103/iju.iju_41_22
Source DB: PubMed Journal: Indian J Urol ISSN: 0970-1591
Figure 1The graphical representation with peaks for complete graph including HPV-16 (FAM) (blue curves), HPV-18 (Rox) (orange curves, and inhibitor controls IC (Hex) (green curves) during the real-time PCR of the DNA samples of Ca penis patients using the HPV-16 and -18 reagents supplied with the kit. HPV: Human papillomavirus, PCR: Polymerase chain reaction, DNA: Deoxyribonucleic acid
Baseline clinicopathological characteristics
| Parameters | Case ( | Control ( |
|
|---|---|---|---|
| Age in years* | 51±15.9 | 43.1±12.2 | 0.06† |
| History of smoking | 15 (37.5) | 6 (30) | 0.57‡ |
| Serum calcium (mg/dL)* | 9.7±0.4 | 8.9±0.4 | 0.001† |
| N stage | |||
| N0 | 8 (20) | - | - |
| N1 | 7 (17.5) | ||
| N2 | 24 (60) | ||
| N3 | 1 (2.5) | ||
| AJCC staging | |||
| Stage 0 | 6 (15) | - | - |
| Stage I | 6 (15) | ||
| Stage II | 14 (35) | ||
| Stage III | 5 (12.5) | ||
| Stage IV | 9 (22.5) | ||
| Tumor differentiation | |||
| Well (G1) | 14 (35) | - | - |
| Moderate (G2) | 23 (57.5) | ||
| Poor (G3) | 3 (7.5) | ||
| Undifferentiated (G4) | - | ||
| Primary treatment | |||
| Circumcision | 1 (2.5) | 20 (100) | - |
| Glansectomy | 1 (2.5) | - | |
| Partial penectomy | 32 (80) | - | |
| Total penectomy | 6 (15) | - |
All values are expressed as n (frequency), except *which is expressed as mean±SD. †Student t-test was used to test for the significance, ‡Chi-square or Fisher’s exact test was used to test for the significance. T: Tumor, N: Nodal, AJCC: American Joint Committee on Cancer, SD: Standard deviation
Prevalence of human papillomavirus subtypes in the study and control groups
| HPV risk groups | HPV subtypes | Cases ( | Controls ( | |
|---|---|---|---|---|
| High-risk HPV types | HPV-16 | 8 (20) | 1 (5) | 0.25 |
| HPV-18 | 7 (17.5) | 2 (10) | 0.70 | |
| HPV-16 or -18 | 11 (27.5) | 2 (10) | 0.19 | |
| Low-risk HPV types | HPV-6 | 5 (12.5) | 1 (5) | 0.65 |
| HPV-11 | 4 (10) | 1 (5) | 0.66 | |
| HPV-6 or -11 | 6 (15) | 2 (10) | 0.70 |
All values are expressed in frequency (%). *Chi-square or Fisher’s exact test was used to test for the significance. HPV: Human papillomavirus
Figure 2The graphical representation of relative E6/7 mRNA expression between PeCa and control tissues for HPV-16 (a and b) and HPV-18 (c and d). mRNA: Messenger ribonucleic acid, PeCa: Penile cancer, HPV: Human papillomavirus
The relative telomerase activity between study and control groups
| Comparison groups | Cases | Controls ( | |
|---|---|---|---|
| Cases ( | 138.66 (9.36-236.14) | 14.46 (4.37-21.77) | 0.0001 |
| High-risk HPV cases ( | 141.90 (9.63-221.01) | 14.46 (4.37-21.77) | 0.0008 |
| High-risk HPV cases ( | 141.90 (9.63-221.01) versus 137.03 (9.36-236.14) | 0.79 | |
All values were expressed in mean (range). *Student t-test was used to test for the significance. P <0.05 signifies statistical significance, †Comparison of relative telomerase activity between cases and controls, ‡Comparison of relative telomerase activity between high-risk HPV cases and controls, §Comparison of relative telomerase activity between high-risk HPV-positive and HPV-negative cases. HPV: Human papillomavirus